2020
DOI: 10.1016/j.cca.2020.10.010
|View full text |Cite
|
Sign up to set email alerts
|

Quantifying apolipoprotein(a) in the era of proteoforms and precision medicine

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
13
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 23 publications
(13 citation statements)
references
References 63 publications
0
13
0
Order By: Relevance
“…It has been reported that the levels of commercially available immunoassays may vary by as much as 32%. 56 Therefore, direct comparisons of the levels between cohorts (YFS versus BHS) or between study years in the YFS may not be possible. For example, our observation suggesting a direct correlation with aging in the YFS (Table S1) could be biased if the levels between subsequent study years are not comparable.…”
Section: Limitationsmentioning
confidence: 99%
“…It has been reported that the levels of commercially available immunoassays may vary by as much as 32%. 56 Therefore, direct comparisons of the levels between cohorts (YFS versus BHS) or between study years in the YFS may not be possible. For example, our observation suggesting a direct correlation with aging in the YFS (Table S1) could be biased if the levels between subsequent study years are not comparable.…”
Section: Limitationsmentioning
confidence: 99%
“…Recently, the theoretical mass of Lp(a) with 6 to 35 K-IV-2 repeats was calculated by Cobbaert and Ruhaak [ 17 ] to range from 2821 to 3344 kD. At the basis of these values, the calculated conversion factors are 3.54–2.99.…”
Section: Lp(a) Structurementioning
confidence: 99%
“…In addition, reporting Lp(a) concentration in mass units (g/L) is metrologically inappropriate, and should be discontinued, given that only apo(a) with its highly variable mass is measured by the antibodies. Furthermore, use of accurate technology, such as mass spectrometry, is required to provide unequivocal molecular characterization and accurate quantitation of apo(a) in molar units, whatever the size polymorphism [59][60][61]. To guarantee that this approach fits with clinical applications, a working group (Apolipoproteins by Mass Spectrometry) has been created by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) to settle issues on commutability of peptide-based compared with recombinant apo(a)-based reference material.…”
Section: Lp(a) Measurement In Clinical Practicementioning
confidence: 99%